Trial Profile
A Phase II, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Jul 2022
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms LADDER
- Sponsors Genentech
- 27 Jun 2022 Results published in the Ophthalmology and Therapy
- 18 Apr 2019 Status changed from active, no longer recruiting to completed.
- 05 Mar 2019 Planned End Date changed from 2 Feb 2019 to 27 Mar 2019.